Stifel Nicolaus Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (ALNY)
Stifel Nicolaus restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report released on Thursday morning. The brokerage currently has a $117.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $123.00.
Several other brokerages also recently issued reports on ALNY. Cowen reissued a buy rating and issued a $147.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 4th. JMP Securities set a $198.00 price objective on Alnylam Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, August 28th. Needham & Company LLC set a $152.00 price objective on Alnylam Pharmaceuticals and gave the stock a buy rating in a research note on Monday, August 27th. ValuEngine raised Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, August 28th. Finally, BidaskClub raised Alnylam Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, July 13th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $141.29.
Alnylam Pharmaceuticals stock traded up $2.94 during mid-day trading on Thursday, hitting $97.90. The company’s stock had a trading volume of 16,884 shares, compared to its average volume of 999,319. The company has a market cap of $9.54 billion, a P/E ratio of -17.70 and a beta of 2.58. The company has a current ratio of 13.22, a quick ratio of 13.22 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a 52-week low of $74.50 and a 52-week high of $153.99.
In related news, CEO John Maraganore sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 25th. The stock was sold at an average price of $105.39, for a total value of $5,269,500.00. Following the transaction, the chief executive officer now directly owns 201,297 shares of the company’s stock, valued at approximately $21,214,690.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Yvonne Greenstreet sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The shares were sold at an average price of $120.00, for a total value of $300,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,916 shares in the company, valued at $229,920. The disclosure for this sale can be found here. Insiders have sold a total of 54,063 shares of company stock valued at $5,733,678 over the last ninety days. Company insiders own 4.30% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $137,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at approximately $170,000. Mutual of America Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 98.5% in the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 960 shares in the last quarter. IPG Investment Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $217,000. Finally, First Republic Investment Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $230,000. 93.36% of the stock is currently owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Story: NASDAQ Stock Market Explained
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.